Could the methylation of *RASSF1A* be the potential epigenetic biomarker for nasopharyngeal carcinoma? – Systematic review and meta-analysis

Thuan Duc Lao

1Faculty of Biotechnology, Ho Chi Minh City Open University, HCMC, Vietnam

Hue Hong Thieu

University of Science, VNU-HCM

Dung Huu Nguyen

University of Medicine and Pharmacy at Ho Chi Minh City

Thuy Ai Huyen Le (✉ thuy.lha@ou.edu.vn)

1Faculty of Biotechnology, Ho Chi Minh City Open University, HCMC, Vietnam <https://orcid.org/0000-0002-4825-3299>

Research article

Keywords: RASSF1A, nasopharyngeal carcinoma, meta-analysis, methylation, tumor suppressor gene

Posted Date: July 1st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-35655/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: *RASSF1A* is a tumor suppressor gene. The methylation of *RASSF1A* has been reported to be associated with the nasopharyngeal tumorigenesis. Aiming to evaluate the association between the *RASSF1A* gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for NPC cancer risk based on meta-analysis.

Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds ratio (OR) were applied to estimate the effect of *CDH-1* methylation based on random-/fix-effects models. Furthermore, subgroup analyses were performed by test-method, ethnicity, source of NPC samples.

Results: Total of 16 studies, included 1,766 samples: 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were enrolled in the meta-analysis. The overall frequency of *RASSF1A* methylation were 55.98% and 1.70% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among included studies. The association between the *RASSF1A* gene methylation and risk of NPC was also confirmed by calculating OR value of 51.43 (95%OR = 28.12-94.08) in fix-effects model ($Q = 10.63$, $p = 0.99$, $I^2 = 0.00$, 95% CI = 0.00-0.00). Additionally, the significant association was also found between the methylation of *RASSF1A* gene and subgroups.

Conclusion: this was the first meta-analysis provided scientific evidences to suggest the *RASSF1A* methylation was the potential biomarker for risk of NPC.

Background

Nasopharyngeal carcinoma (NPC), a prevalent nasopharyngeal malignant tumor with the remarkable differences in distribution, gravitating toward Southern Asia [1–7]. According to the data from Global Cancer Observatory, updated to 2018, 129,079 new nasopharyngeal cases were recorded in the world, of which 72,987 nasopharyngeal death cases were occurred. Even though improvements in nasopharyngeal cancer treatment have been achieved, the diagnosis at an advanced stage led to reduce the success rate of treatment as well as the survival of patients. Thus, the early screening and diagnosis represents the beneficial opportunities to increase the survival of patients as well as the effects of nasopharyngeal cancer treatment. Because of the non-specific symptoms related to the early stage of NPC as well as the deeply seated location of nasopharynx, it leads to the major obstacle to early screening of NPC [8]. Therefore, effective biomarkers are truly needed [9]. Today, much efforts have been made for identification of early biomarkers based on focusing the etiological factors led to the nasopharyngeal tumorigenesis. The progression of NPC is a multiple steps associated with multiple factors, including the infection of Epstein-Barr Virus (EBV), environmental factors, as well as genetic and epigenetics alterations [10, 11]. Among them, DNA hypermethylation has been postulated as the best-studied epigenetic alterations in tumorigenesis [12]. The phenomenon of tumor suppressor gene's (TSG) promoter cause the

transcriptional silencing, led to gene inactivation, which inhibit the functions of those genes, resulting in the cancer development [13, 14].

Many TSGs have been recorded to be involved in the critical cancer-related cellular pathways. Thus, the patterns of TSG promoters' methylation have been studied, and reported to be acted as the potential epigenetic biomarkers for NPC [9, 12]. *RASSF1A* (RAS-association domain family 1 isoform A), located 3p21.31, belonged to the family of RAS effectors, is a tumor suppressor gene coding protein. It functioned as the protein that modulates multiple apoptotic, cell cycle pathways and DNA repair process [15, 16]. Increasing evidences demonstrated that the inactivation of *RASSF1A* due to the hypermethylation, has been reported to associated with the pathogenesis of NPC. However, due to the different sensitivities and intra/inter-assay coefficients of variation of methods, the reported frequency of *RASSF1A* hypermethylation and its prognostic value is highly variable. Therefore, in current study, we performed the meta-analysis is to summarize the previously studies and identify the diagnosis and early screening value of *RASSF1A* for NPC.

Methods

Search strategy and inclusion/exclusion criteria

We conducted a comprehensive search strategy towards the guidelines of Preferred Reporting Items for Systematics Reviews and Meta-Analyses [17]. By using separation or combination of following keywords: "Nasopharyngeal carcinoma", "methylation", "RASSF1A", "diagnosis", "prognosis", "epigenetic", "hypermethylation", were applied to search reveal published articles in MEDLINE database (Updated on December, 2019). Additional studies were also identified via the references listed in the articles.

Studies were deeply considered eligible only when they met all of the following inclusion criteria: i) The articles were limited to studies written in English; ii) case-control study designed; iii) provided that data about the frequency of *RASSF1A* methylation as well as the sample size in both case and control group. Exclusion criteria were as follows: i) The articles were written in other languages; ii) abstracts, case reports, letter to editor or unpublished articles were eliminated; iii) studies were related to other tumors and not specific for NPC; iv) studies lacked vital information for analysis.

Data extraction

The eligibility of each study, the relevant data from the eligible studies were independently retrieved by two authors. Disagreements were resolved through discussion within the third author or our research team. The relevant data were extracted from each study according to the data form, including first Author's last name, year of publication, country where the study was performed, sample type, experimental methods to assess the methylation of *RASSF1A*, and number of cases and controls subjects.

Statistical analysis, publication bias and sensitivity analysis

MedCalc® software, by MedCalc Software Ltd, was applied to statistically analyze extracted data (<https://www.medcalc.org/>). The frequency of *RASSF1A* methylation was calculated in both case and control group. The strength of association between *RASSF1A* methylation and NPC was evaluated by Odds ratio (OR) with 95% confidence intervals (95%CI). In current study, the heterogeneity among the included studies was estimated by the Cochran Q test and I^2 statistics [18]. The cut-off point: $p = 0.05$ for the Q test and I^2 were used to test the heterogeneity between studies. The scale of I^2 value is classified as following: $I^2 < 25\%$: no heterogeneity, $25\% \leq I^2 \leq 50\%$: moderate heterogeneity, and $I^2 > 50\%$: strong heterogeneity [18-20]. The random-effects model was applied if the heterogeneity among studies existed ($p < 0.05$ for Q test, $I^2 > 50\%$). In the case of no between-study heterogeneity, a fixed-effects model was applied to compute the pooled ORs. In order to determine the presence of publication bias, the symmetry of the funnel plots in which ORs were plotted against their corresponding standard errors were assessed by the Begg's funnel plot and Egger's test ($p < 0.05$) indicates statistically significant [21,22]. Additionally, the sensitivity analysis was also performed by sequential omission of individual studies to evaluate stability of the results.

Results

Study characteristics

After exclusion of studies that not met the inclusion criteria, finally, 16 studies, published from 2001 to 2015, included 1,766 samples: 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were enrolled in the meta-analysis. The characteristics of included studies of *RASSF1A* methylation and risk of NPC were summarized in Table 1.

The number of NPC samples included studies ranged from 6 to 220 (mean: 42.07 ± 38.90), and number of control samples included studies ranged from 2 to 50 (mean: 21.78 ± 17.38). The patients' ethnicity in 16 studies, comprised of 14 studies from Asian countries: China, Hong Kong, Singapore, Taiwan (counting for 87.50%), and 2 studies from African country: Tunisia (counting for 12.5%). Regarding to the test-method of *RASSF1A* methylation, twelve studies used MSP (counting for 75.00%), one study used COBRA (counting for 6.25%), one study used RT-qPCR (counting for 6.25%), one study used MMSP (counting for 6.25%), one study used MS-HRM counting for 6.25%).

Meta-analysis: The frequency of *RASSF1A* promoter methylation, and the association between *RASSF1A* gene methylation and NPC

The differences of *RASSF1A* gene methylation between the case-group and control-group in 16 studies, including 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were accessed. Concerning to the heterogeneity between studies, as there was heterogeneity across studies in the case-group ($Q = 443.5$, $p < 0.0001$, $I^2 = 93.91\%$, 95%CI for $I^2 = 92.23-95.23$), and no heterogeneity across studies in the control-group ($Q = 9.67$, $p = 1.00$, $I^2 = 0.00\%$, 95%CI for $I^2 = 0.00-0.00$), thus, the random-effects model and fix-effects model were applied to calculate the frequency of *RASSF1A*

gene in case-group and control-group, respectively (Fig. 1, Fig. 2). As the results, the frequency of *RASSF1A* gene methylation in case-group and control-group were 55.98% (ranged from 0.00% to 100.00%; 95% CI = 42.28-67.35) and 1.70% (ranged from 0.00 to 4.88%; 95% CI = 0.83-3.06), respectively. The meta-analysis result also indicated that the frequency of *RASSF1A* gene methylation in case-group was significant higher than control group.

The methylation of *RASSF1A* gene was significantly associated with an increased NPC risk with a pooled of Odds ratio (OR) of 33.40 (95%CI = 20.22-55.16) based on the fix-effect model ($Q = 29.56$, $p = 0.29$, $I^2 = 12.05\%$, 95%CI = 0.00-44.45) (Fig. 3). The funnel plot of pooled analysis, which was small asymmetric, indicated that there was still small bias among included studies, therefore publication bias cannot be completely excluded as a factor of influence on the present meta-analysis. In additionally, the sensitivity analysis found that study by Chang et al. (2003) (OR = 1.54, 95%CI = 0.09-24.10), Chang et al. (2003) (OR = 0.46, 95%CI = 0.02-11.79) and Tian et al. (2013) (OR = 4.14, 95%CI = 0.80-21.29) were the relative poor-quality studies. Therefore, those studies were omitted to evaluate again the association between the methylation of *RASSF1A* gene and NPC risk through OR. As the result, the between heterogeneity decreased to $I^2 = 0.00\%$ ($p = 0.99$), indicated that no heterogeneity among enrolled studies was observed. Additionally, the association between *RASSF1A* methylation and risk of NPC increased, which was indicated by the increased OR of 51.43 (95%OR = 28.12-94.08) in fix-effects model ($Q = 10.63$, $p = 0.99$, $I^2 = 0.00$, 95% CI = 0.00-0.00) (Fig. 5) (compared to previously calculated OR of 33.40). Moreover, the funnel plot of pooled analysis, which was quite symmetric, indicated that there was no significant bias among the included studies (Fig. 6).

The subgroup analysis by ethnicity, test-method, as well as source of sample were performed. The results of subgroup analysis showed that the heterogeneity totally disappeared in all subgroup (Asian vs non-Asian countries, MPS vs other test-methods, tissue vs other source of samples, $I^2 = 0.00$, $p > 0.05$) (Table 2). With respect to the subgroups categorized by ethnicity, the significantly association between *RASSF1A* methylation and risk of NPC was observed among the Asian country and non-Asian countries in the fix-effect model (Asian countries: OR = 47.94, 95%CI = 25.61-89.75; non-Asian countries: OR = 135.96, 95%CI = 16.03-1,153.41). The subgroup analysis by source of NPC samples, there was a strong association between *RASSF1A* methylation and NPC among the NPC biopsy tissue group and non-biopsy group, including nasopharyngeal swab, mouth and rinsing fluid, plasma, blood in the fix-effect model (Biopsy tissue: OR = 55.29, 95%CI = 27.25-112.208; Non-biopsy: OR = 45.76, 95%CI = 15.56-134.60). Additionally, significant association between *RASSF1A* methylation and NPC risk among test-method subgroup was found in fix-effects model (MSP: OR = 40.86, 95%CI = 20.41-81.80; Other methods: OR = 76.24, 95%CI = 23.24-250.11).

Sensitivity analysis and publication bias

After removing the relative poor-quality study, the quite symmetric funnel plot, suggested there was no significant bias among included studies, was observed (Fig. 6). Additionally, the sensitivity analysis was performed to evaluate the stability and reliability of the conclusions according to the leave-one-out

method by excluding one study. As the results, the pooled OR was ranged from 41.95 (95%CI = 22.13-79.49) to 55.06 (95%CI = 29.63-102.32) under the fix-effects model within the $I^2 = 0.00$ ($p > 0.05$) (Table 3), which confirmed the stability and reliability of the results. Therefore, the results, and conclusion of present meta-analysis, which was to evaluate the association between methylation of *RASSF1A* and NPC risk, were stable and reliable.

Discussion

It is important to find out the effective biomarker for early screening of NPC. Based on the etiological factors of NPC, the methylation of TSGs promoter has been recognized as the common mechanism of the inactivation of TSG, leading to the tumorigenesis of NPC [13,39]. According to Xiong et al. (2004), they identified the susceptibility locus at the chromosome 3p21 linked to the NPC tumorigenesis based on the genome-wide linkage analyses of high-risk Chinese NPC patients [40]. *RASSF1A*, belonged this region, is reported as the tumor suppressor gene. The inactivation of *RASSF1A* via the methylation has been recognized as highly associated with the progression of NPC [41,42]. Notably that the methylation of TSGs promoter is reported as one of the earlier molecular modification during the human epithelial cells transformed to malignancy, and often occurred earlier than the changes of morphology of cancer [43]. Hence, the analysis of TSG hypermethylation, including *RASSF1A*, may be served as the potential epigenetic biomarker for early screening of NPC. As previous reports, the frequency of *RASSF1A* methylation in NPC was is highly variable, to determine whether *RASSF1A* methylation could be served as potential biomarkers for NPC, the meta-analysis and the subgroup analysis by ethnicity, source of samples, and test-methods were performed.

To our knowledge, this was the first meta-analysis of previous published studies, revealed that methylation of *RASSF1A* does the increasing of NPC, to evaluate the relationship between *RASSF1A* promoter and NPC tumorigenesis. In this meta-analysis, sixteen published studies included 1,766 samples: 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were enrolled. As the results, the overall frequency of *RASSF1A* methylation in the NPC and control-group were 55.98% (ranged from 0.00% to 100.00%; 95% CI = 42.28-67.35) and 1.70% (ranged from 0.00 to 4.88%; 95% CI = 0.83-3.06), respectively. It could be observed that the individuals with *RASSF1A* gene methylation was significantly associated with NPC based on the calculation of OR (OR = 33.40; 95%CI = 20.22-55.16) based on the fix-effect model (Fig. 3). However, the funnel plot as well as the sensitivity analysis found out that small bias among included studies still appeared. Therefore, the relative poor-quality studies, including study by Chang et al. (2003) (OR = 1.54, 95%CI = 0.09-24.10), Chang et al. (2003) (OR = 0.46, 95%CI = 0.02-11.79) and Tian et al. (2013) (OR = 4.14, 95%CI = 0.80-21.29) were removed. The heterogeneity between studies decreased to I^2 of 0.00 in the fix-effects model. The resulting OR is 51.43 with a 95%CI ranged from 28.12 to 94.08, indicating a 51.43-fold increased odds of a positive outcome, and this increase was statistically significant at the 5% level. Therefore, the methylation of *RASSF1A* was significantly associated with the NPC tumorigenesis. It suggested the methylation of *RASSF1A* might play a crucial role in the pathogenesis of NPC. By subgroup analysis, the

significant association between *RASSF1A* gene methylation and NPC risk were found among in all subgroups, including ethnicity, source of samples and test-method. Regarding to the ethnicity, a significant association between methylation of *RASSF1A* and NPC was found among the Asian region and the Non-Asia region. Additionally, most studies was performed in Asian region (14 of 16 studies), only two studies was done in Africa, thus, one again confirmed the nasopharyngeal cancer is native and posed to Asian region. The subgroup analysis by source of cancer samples revealed a significant correlation in both subgroup: biopsy samples and non-biopsy samples, and no heterogeneity was observed. It indicated that the type of biopsy was more suitable to apply to evaluate the methylation of *RASSF1A* gene. However, the source of non-biopsy samples, including nasopharyngeal swab, mouth and rinse, plasma – type of non/less-invasive source of sample, could be reflect alterations in the NPC and facility of collecting NPC samples led it a potential biomarker for early screening of NPC. Therefore, it should be focused on in the future to find out the non/less-invasive biomarker for NPC. The MSP method was used in twelve studies used MSP (counting for 75.00%). It could be explained MSP is the “gold standard method” of evaluation of methylation. The MSP shows the useful tool for the qualitative DNA methylation analysis within the ease of design and execution, sensitivity in the ability to detect small quantities of methylated DNA [44]. Moreover, in which MSP products are run on a gel, and the results are reported as methylated or unmethylated at the target DNA sequence [45]. These results are in accordance with that documented *RASSF1A* gene methylation to be the common and early epigenetic event in the progression of NPC tumorigenesis. So its epigenetic event might could be used as the potential epigenetic biomarker for risk of NPC. However, the current meta-analysis exhibited some limitations due to the number of current enrolled studies of 16, the data of non-English language studies may contribute to some bias, as well as the evaluation of the correlation between methylation of *RASSF1A* gene and clinicopathological features, age and the TNM stage which are differences in *RASSF1A* methylation between cases and controls.

Conclusion

This meta-analysis highlighted the significant association between the methylation of *RASSF1A* gene and risk of NPC based on the evaluation of frequency of both case-group, counting for 55.98% and control-group, counting for 1.70%, as well as OR value of 51.43. Additionally, our findings underscore the correlation among *RASSF1A* gene methylation and all subgroups, including region, source of samples, and test-method. The finding in present meta-analysis emphasized that the methylation of *RASSF1A* gene was recorded as the early epigenetic event in the progression of NPC tumorigenesis based on the literature-based meta-analysis.

Tables

Table 1. The characteristics of studies included in the meta-analysis of *RASSF1A* methylation and risk of NPC

Author, Reference	Year	Region	Case		Control		Method	Source of	
			N	P	N	P		Case	Control
Chow et al.	2004	Asia	26	20	-	-	COBRA	B	-
Chang et al.	2003	Asia	30	20	6	0	MSP	B	B
Chang et al.	2003	Asia	30	10	37	0	MSP	S	S
Chang et al.	2003	Asia	30	11	43	0	MSP	MT	MT
Chang et al.	2003	Asia	30	1	43	1	MSP	PI	PI
Chang et al.	2003	Asia	30	0	43	1	MSP	Bf	Bf
Kwong et al.	2002	Asia	29	24	6	0	MSP	B	B
Wong et al.	2004	Asia	41	2	43	0	RT-qPCR	PI	BI
Challouf et al.	2012	Africa	36	27	19	0	MSP	B	B
Zhou et al.	2005	Asia	28	23	8	0	MSP	B	B
Zhou et al.	2005	Asia	28	21	8	0	MSP	B	B
Zhou et al.	2005	Asia	28	13	8	0	MSP	B	B
Wang et al.	2009	Asia	38	27	14	0	MSP	B	B
Hutajulu et al.	2011	Asia	53	40	25	1	MSP	B	S
Fendri et ai.	2009	Africa	68	62	9	0	MSP	B	B
Tong et al.	2002	Asia	28	11	12	0	MSP	S	S
Tong et al.	2002	Asia	16	11	12	0	MSP	B	S
Zhang et al.	2012	Asia	49	39	20	0	MSP	B	S
Zhang et al.	2012	Asia	49	29	20	0	MSP	S	S
Wong et al.	2003	Asia	28	13	5	0	MSP	B	B
Wong et al.	2003	Asia	6	6	5	0	MSP	B	B
Qiu et al.	2004	Asia	27	20	3	0	MSP	B	B
Tian et al.	2013	Asia	40	7	41	2	MSP	BI	BI
Lo et al.	2001	Asia	21	14	6	0	MSP	B	B
Lo et al.	2001	Asia	21	14	2	0	MSP	B	B
Yang et al.	2015	Asia	52	36	50	0	MS-HRM	B	PI
Yang et al.	2015	Asia	96	66	50	0	MS-HRM	S	PI

Note: MSP: Methylation-specific PCR; COBRA: combined bisulfite restriction analysis; MS-HRM: Methylation-sensitive high resolution melting; RT-qPCR: Real-Time Quantitative PCR; B: tumor biopsy; PI: plasma, Bf: buffy coat; MT: Mouth-throat rinsing fluid; S: nasopharyngeal swab; Bl: blood; -: not recorded; P: positive; N: total samples

Table 2. Summary of subgroup analysis in meta-analysis of *RASSF1A* methylation and NPC risk

Group	Case		Control		Model, OR, 95% CI (Fix-effects model)	Heterogeneity	
	N	P	N	P		I ² (%)	P
Total	1,052	592	461	1	51.43, 28.12-94.08	0.00	0.99
Ethnicity							
Asia	948	503	433	1	47.94, 25.61-89.75	0.00	0.99
Non-Asia	104	89	28	0	135.96, 16.03-1,153.41	0.00	0.82
Sources of sample							
Biopsy sample	558	410	206	1	55.29, 27.25-112.208	0.00	0.98
Non-biopsy	494	182	255	0	45.76, 15.56-134.60	0.00	0.73
Test-methods							
MSP	545	367	228	1	40.86, 20.41-81.80	0.00	1.00
Other test-method	507	225	233	0	76.24, 23.24-250.11	0.00	0.48

Table 3. Sensitivity analysis of methylation of *RASSF1A* and NPC risk by the fix-effects model

	OR, 95% CI	Heterogeneity	
		I ² , 95% CI	P
Omitting Lo et al. 2001	54.81, 29.12-103.17	0.00, 0.00-0.00	0.99
Omitting Kwong et al. 2002	51.28, 27.74-94.77	0.00, 0.00-0.00	0.98
Omitting Tong et al. 2002	53.98, 28.72-101.45	0.00, 0.00-0.00	0.98
Omitting Chang et al. 2003	53.42, 27.96-102.28	0.00, 0.00-0.00	0.96
Omitting Wong et al. 2003	54.02, 28.96-100.77	0.00, 0.00-0.00	0.99
Omitting Wong et al. 2004	55.06, 29.63-102.32	0.00, 0.00-0.00	1.00
Omitting Qiu et al. 2004	52.69, 28.44-97.60	0.00, 0.00-0.00	0.98
Omitting Zhou et al. 2005	53.68, 28.19-102.20	0.00, 0.00-0.00	0.97
Omitting Wang et al. 2009	50.80, 27.42-94.14	0.00, 0.00-0.00	0.98
Omitting Fendri et al. 2009	49.69, 26.90-91.78	0.00, 0.00-0.00	0.99
Omitting Hutajulu et al. 2011	50.18, 26.79-93.99	0.00, 0.00-0.00	0.98
Omitting Challouf et al. 2012	49.76, 26.86-92.18	0.00, 0.00-0.00	0.98
Omitting Zhang et al. 2012	48.46, 25.76-91.14	0.00, 0.00-0.00	0.98
Omitting Yang et al. 2015	41.95, 22.13-79.49	0.00, 0.00-0.00	0.99

Abbreviations

COBRA: Combined bisulfite restriction analysis

MMSP: Multiplex methylation-specific PCR

MS-HRM: Methylation-Sensitive High Resolution Melting

MSP: Methylation-specific PCR

NPC: Nasopharyngeal carcinoma

OR: Odds ratio

RASSF1A: RAS-association domain family 1 isoform A

RT-qPCR: Real-time quantitative PCR

TSG: tumor suppressor gene

Declarations

Ethics approval and consent to participate

This is an observation and review study, no ethics and consent applied

Funding Information

This study was funded by Ho Chi Minh City Department of Science and Technology, Ho Chi Minh City, Vietnam (Grant No. 42/2017/HD-SKHCN), and Ho Chi Minh City Open University, Ho Chi Minh City, Vietnam.

Author contribution

Lao DT conceived, designed, performed, analyzed data, wrote the draft manuscript and acted as primary author for the project, Thieu HH, Nguyen HD contributed to perform and analyze data. Le HAT designed, performed, analyzed data, oversaw the research and edited the article.

Conflicts of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article

Acknowledgements

We wish to express our thanks to the research project sponsored by Ho Chi Minh City Department of Science and Technology, Ho Chi Minh City, Vietnam and Ho Chi Minh City Open University, Ho Chi Minh City, Vietnam

References

1. Sham JS, Wei WI, Zong YS, et al (1990) Detection of subclinical nasopharyngeal carcinoma by fiberoptic endoscopy and multiple biopsy. *Lancet* 335(8686):371-374. Doi: 10.1016/0140-6736(90)90206-K.
2. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K (2009) The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. *Virus Res* 143(2):209-221. Doi: 10.1016/j.virusres.2009.07.005.
3. Cao SM, Simons MJ, Qian CN (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. *Chin J Cancer* 30(2):114-119. Doi: 10.5732/cjc.010.10377.
4. MahdaviFar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H (2016) Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Health Res Perspect* 7(6):360-72. Doi: 10.1016/j.phrp.2016.11.002.

5. Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA (2018a) miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. *Braz Oral Res* 32:e126. Doi: 10.1590/1807-3107bor-2018.vol32.0126.
6. Lao TD, Nguyen DH, Le THA (2018b) Study of mir-141 and its Potential Targeted mRNA PTEN Expression in Nasopharyngeal Carcinoma: From in Silico to Initial Experiment Analysis. *AJPRHC* 10(3):66-74. Doi: 18311/ajprhc/2018/22341.
7. Lao TD, Le THA (2020) Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: an update report. *Adv life sci* 7(2):86-90.
8. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A (2011) Early detection of nasopharyngeal carcinoma. *Int J Otolaryngol* 2011:638058. Doi: 10.1155/2011/638058.
9. Li M, Wang C, Yu B, Zhang X, Shi F, Liu X (2019) Diagnostic value of *RASSF1A* methylation for breast cancer: a meta-analysis. *Biosci Rep* 39(6): BSR20190923. Doi: 10.1042/BSR20190923.
10. Tao Q, Chan AT (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. *Expert Rev Mol Med* 9(12):1-24. Doi: 10.1017/S1462399407000312.
11. Tsao SW, Yip YL, Tsang CM, et al (2014) Etiological factors of nasopharyngeal carcinoma. *Oral Oncol* 50(5):330-338. Doi: 10.1016/j.oraloncology.2014.02.006.
12. Wu K, Xu XN, Chen Y, Pu XL, Wang BY, Tang XD (2015) *RASSF1A* gene methylation is associated with nasopharyngeal carcinoma risk in Chinese. *Asian Pac J Cancer Prev* 16(6):2283-2287. Doi: 10.7314/apjcp.2015.16.6.2283.
13. Wang LH, Wu CF, Rajasekaran N, Shin YK (2018) Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. *Cell Physiol Biochem* 51(6):2647-2693. Doi: 10.1159/000495956.
14. Locke WJ, Guanzon D, Ma C, et al (2019) DNA Methylation Cancer Biomarkers: Translation to the Clinic. *Front Genet* 10:1150. Doi: 10.3389/fgene.2019.01150.
15. Donninger H, Vos MD, Clark GJ (2007) The *RASSF1A* tumor suppressor. *Journal of Cell Science* 120:3163-3172. Doi: 10.1242/jcs.010389.
16. Donninger H, Clark J, Rinaldo F, et al (2015) The *RASSF1A* tumor suppressor regulates XPA-mediated DNA repair. *Mol Cell Biol* 35(1):277-287. Doi: 10.1128/MCB.00202-14.
17. Moher D, Liberati A, Tetzlaff J, et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 6(7):e1000097. Doi: 10.1371/journal.pmed.1000097.
18. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* 21(11):1539-1558. Doi: 10.1002/sim.1186.
19. DerSimonian R (1996) Meta-analysis in the design and monitoring of clinical trials. *Stat Med* 15(12):1237-1248. Doi: 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327(7414):557-560.
21. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* 50(4):1088-1101. Doi: 10.2307/2533446.

22. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315(7109):629-634. Doi: 1136/bmj.315.7109.629.
23. Chow LS, Lo KW, Kwong J, et al (2004) *RASSF1A* is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. *Int J Cancer* 109(6):839-47. Doi: 1002/ijc.20079.
24. Chang HS, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW (2003) Evaluation Of Hypermethylated Tumor Suppressor Genes As Tumor Markers In Mouth And Throat Rinsing Fluid, Nasopharyngeal Swab And Peripheral Blood Of Nasopharyngeal Carcinoma Patient. *Int. J. Cancer* 105:851-855. Doi: 1002/ijc.11162.
25. Kwong J, Lo KW, To KF, Teo PML, Johnson PJ, Huang DP (2002) Promoter Hypermethylation of Multiple Genes in Nasopharyngeal Carcinoma. *Clinical Cancer Research* 8:131-837.
26. Wong TS, Kwong DLW, Sham JST, Wei WI, Kwong YL, Yuen APW (2004) Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma. *Clinical Cancer Research* 10:2401-2406. Doi: 10.1158/1078-0432.CCR-03-0139.
27. Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Gacem RB, Trimeche M (2012) Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. *Clinica Chimica Acta* 413:795-802. Doi: 1016/j.cca.2012.01.018.
28. Zhou L, Jiang W, Ren C, et al (2005) Frequent Hypermethylation of *RASSF1A* and *TSLC1*, and High Viral Load of Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma and Matched Tumor-Adjacent Tissues. *Neoplasia* 7(9):809-815. Doi: 1593/neo.05217.
29. Wang T, Liu H, Chen Y, Liu W, Yu J, Wu G (2009) Methylation associated inactivation of *RASSF1A* and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. *J Exp Clin Cancer Res* 28(1):160. doi: 10.1186/1756-9966-28-160.
30. Hutajulu SH, Indrasari SR, Indrawati LP, et al (2011) Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. *Mol Cancer* 10:48. Doi: 10.1186/1476-4598-10-48.
31. Fendri A, Masmoudi A, Khabir A, et al (2009) Inactivation of *RASSF1A*, *RARβ2* and *DAP-kinase* by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. *Cancer Biology & Therapy* 8(5):1-8. Doi: 4161/cbt.8.5.7686.
32. Tong JHM, Tsang RKY, Lo KW, et al (2002) Quantitative Epstein-Barr Virus DNA Analysis and Detection of Gene Promoter Hypermethylation in Nasopharyngeal (NP) Brushing Samples from Patients with NP Carcinoma. *Clinical Cancer Research* 8:2612-9.
33. Zhang Z, Sun D, Hutajulu SH, et al (2012) Development of a Non-Invasive Method, Multiplex Methylation Specific PCR (MMSP), for Early Diagnosis of Nasopharyngeal Carcinoma. *PLOS ONE* 7(11):e45908. Doi: 1371/journal.pone.0045908
34. Wong TS, Tang KC, Kwong DLW, et al (2003) Differential gene methylation in undifferentiated nasopharyngeal carcinoma. *International Journal Of Oncology* 22:869-74. Doi: 10.3892/ijo.22.4.869.
35. Qiu GH, Tan LKS, Loh KS, et al (2004) The candidate tumor suppressor gene *BLU*, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both

- epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Oncogene* 23:4793–806. Doi: 10.1038/sj.onc.1207632.
36. Tian F, Yip SP, Kwong DLW, Lin Z, Yang Z, Wu VWC (2013) Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. *Cancer Epidemiology* 37:708–13. Doi: 10.1016/j.canep.2013.05.012.
 37. Lo KW, Kwong J, Hui ABY, et al (2001) High Frequency of Promoter Hypermethylation of RASSF1A in Nasopharyngeal Carcinoma. *Cancer Research* 61:3877-81. Doi:
 38. Yang X, Dai W, Kwong DLW, et al (2015) Epigenetic Markers for Non-invasive Early Detection of Nasopharyngeal Carcinoma by Methylation-Sensitive High Resolution Melting. *International Journal of Cancer* 136 (4):1-29. Doi: 10.1002/ijc.29192.
 39. Rountree MR, Bachman KE, Herman JG, Baylin SB (2001) DNA methylation, chromatin inheritance, and cancer. *Oncogene* 20(24):3156-3165. Doi: 10.1038/sj.onc.1204339.
 40. Xiong W, Zeng ZY, Xia JH (2004) A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. *Cancer Res* 64(6):1972-1974. Doi: 10.1158/0008-5472.can-03-3253.
 41. Hui AB, Lo KW, Leung SF, et al (1999) Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. *Int J Cancer* 82(4):498-503. Doi: 10.1002/(sici)1097-0215(19990812)82:4<498::aid-ijc5>3.0.co;2-s.
 42. Wang T, Liu H, Chen Y, Liu W, Yu J, Wu G (2009) Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. *Journal of Experimental & Clinical Cancer Research* 28(160):1-11. Doi: 10.1186/1756-9966-28-160.
 43. Zhang J, Shen Z, Liu H, Liu S, Shu W (2018) Diagnostic potential of methylated DAPK in brushing samples of nasopharyngeal carcinoma. *Cancer Manag Res* 28;10:2953-2964. Doi: 10.2147/CMAR.S171796.
 44. Huang Z, Bassil CF, Murphy SK (2013) Methylation-specific PCR. *Methods Mol Biol* 1049:75-82. https://doi.org/10.1007/978-1-62703-547-7_7.
 45. Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M (2015) DAPK1 Promoter Methylation and Cervical Cancer Risk: A Systematic Review and a Meta-Analysis. *PLoS One* 10(8):e0135078. Doi: 10.1371/journal.pone.0135078.

Figures

Study, year, frequency, 95% CI, weight

Lo et al. 2001, 66.67%, 43.03-85.41, 3.46%

Lo et al. 2001, 66.67%, 43.03-85.41, 3.46%

Kwong et al. 2002, 82.76%, 64.23-94.15, 3.56%

Tong et al. 2002, 39.29%, 21.50-59.42, 3.55%

Tong et al. 2002, 68.75%, 41.34-88.98, 3.35%

Chang et al. 2003, 66.67%, 47.19-82.71, 3.57%

Chang et al. 2003, 33.33%, 17.29-52.81, 3.57%

Chang et al. 2003, 36.67%, 19.93-56.14, 3.57%

Chang et al. 2003, 3.33%, 0.08-17.22, 3.57%

Chang et al. 2003, 0.00%, 0.00-11.57, 3.57%

Wong et al. 2003, 46.43%, 27.51-66.13, 3.55%

Wong et al. 2003, 100.00%, 54.07-100.00, 2.80%

Chow et al. 2004, 76.92%, 56.35-91.03, 3.53%

Wong et al. 2004, 4.88%, 0.60-16.53, 3.65%

Qiu et al. 2004, 74.07%, 53.72-88.89, 3.54%

Zhou et al. 2005, 82.14%, 63.11-93.94, 3.55%

Zhou et al. 2005, 75.00%, 55.13-89.31, 3.55%

Zhou et al. 2005, 46.43%, 27.51-66.13, 3.55%

Wang et al. 2009, 71.05%, 54.10-84.58, 3.63%

Fendri et al. 2009, 91.18%, 81.78-96.69, 3.74%

Hutajulu et al. 2011, 75.47%, 61.72-86.25, 3.70%

Challouf et al. 2012, 75.00%, 57.80-87.88, 3.62%

Zhang et al. 2012, 79.59%, 65.66-89.76, 3.69%

Zhang et al. 2012, 59.18%, 44.21-73.00, 3.69%

Tian et al. 2013, 17.50%, 7.34-32.78, 3.64%

Yang et al. 2015, 69.23%, 54.90-81.28, 3.70%

Yang et al. 2015, 68.75%, 58.48-77.83, 3.78%

Yang et al. 2015, 24.09%, 18.60-30.39, 3.84%

Total (random effects): 55.98%, 44.28-67.35, 100.00%

Q= 443.25;

p<0.0001;

I²= 93.91%;

95%CI for I²= 92.23-95.23

Figure 1

Forest plot of frequency of RASSF1A gene methylation detected in NPC samples

Study, year, frequency, 95% CI, weight

Chang et al. 2003, 0.00%, 0.00-45.93, 1.14%

Chang et al. 2003, 0.00%, 0.00-9.49, 6.18%

Chang et al. 2003, 0.00%, 0.00-8.22, 7.15%

Chang et al. 2003, 2.33%, 0.06-12.29, 7.15%

Chang et al. 2003, 2.33%, 0.06-12.29, 7.15%

Kwong et al. 2002, 0.00%, 0.00-45.93, 1.14%

Wong et al. 2004, 0.00%, 0.00-8.22, 7.15%

Challouf et al. 2012, 0.00%, 0.00-17.65, 3.25%

Zhou et al. 2005, 0.00%, 0.00-36.94, 1.46%

Zhou et al. 2005, 0.00%, 0.00-36.94, 1.46%

Zhou et al. 2005, 0.00%, 0.00-36.94, 1.46%

Wang et al. 2009, 0.00%, 0.00-23.16, 2.44%

Hutajulu et al. 2011, 4.00%, 0.10-20.35, 4.23%

Fendri et al. 2009, 0.00%, 0.00-33.63, 1.63%

Tong et al. 2002, 0.00%, 0.00-26.47, 2.11%

Tong et al. 2002, 0.00%, 0.00-26.47, 2.11%

Zhang et al. 2012, 0.00%, 0.00-16.84, 3.41%

Zhang et al. 2012, 0.00%, 0.00-16.84, 3.41%

Wong et al. 2003, 0.00%, 0.00-52.18, 0.98%

Wong et al. 2003, 0.00%, 0.00-52.18, 0.98%

Qiu et al. 2004, 0.00%, 0.00-70.76, 0.65%

Tian et al. 2013, 4.88%, 0.60-16.53, 6.83%

Lo et al. 2001, 0.00%, 0.00-45.93, 1.14%

Lo et al. 2001, 0.00%, 0.00-84.19, 0.49%

Yang et al. 2015, 0.00%, 0.00-7.11, 8.29%

Yang et al. 2015, 0.00%, 0.00-7.11, 8.29%

Yang et al. 2015, 0.00%, 0.00-7.11, 8.29%

Total (fixed effects): 1.70%, 0.83-3.06, 100.00%

Q= 9.67;

p=1.00;

I²= 0.00%;

95% CI for I²= 0.00-0.00

Figure 2

Forest plot of frequency of RASSF1A gene methylation detected in control samples

Study, year, Odds ratio, 95% CI, weight

Chang et al 2003, 25.38, 1.30-495.27, 3.31%
 Chang et al 2003, 38.42, 2.14-689.63, 3.51%
 Chang et al 2003, 51.31, 2.88-915.31, 3.52%
 Chang et al 2003, 1.45, 0.09-24.10, 3.70%
 Chang et al 2003, 0.46, 0.02-11.79, 2.80%
 Kwong et al 2002, 57.91, 2.82-1188.42, 3.20%
 Wong et al 2004, 5.51, 0.26-118.24, 3.11%
 Challouf et al 2012, 112.90, 6.20-2056.82, 3.47%
 Zhou et al 2005, 72.64, 3.62-1458.24, 3.25%
 Zhou et al 2005, 48.73, 2.50-950.73, 3.31%
 Zhou et al 2005, 14.81, 0.78-281.22, 3.38%
 Wang et al 2009, 69.35, 3.81-1262.92, 3.47%
 Hutajulu et al 2011, 73.85, 9.08-600.63, 6.66%
 Fendri et al 2009, 182.69, 9.50-3512.78, 3.35%
 Tong et al 2002, 16.43, 0.88-305.53, 3.42%
 Tong et al 2002, 52.27, 2.59-1053.97, 3.24%
 Zhang et al 2012, 154.24, 8.60-2766.44, 3.51%
 Zhang et al 2012, 59.00, 3.37-1031.78, 3.57%
 Wong et al 2003, 9.58, 0.48-189.69, 3.28%
 Wong et al 2003, 143.00, 2.42-8467.64, 1.76%
 Qiu et al 2004, 19.13, 0.88-415.91, 3.09%
 Tian et al 2013, 4.14, 0.80-21.29, 10.90%
 Lo et al 2001, 25.13, 1.24-509.15, 3.23%
 Lo et al 2001, 9.67, 0.41-228.26, 2.93%
 Yang et al 2015, 223.42, 12.98-3845.49, 3.61%
 Yang et al 2015, 220.21, 13.15-3688.32, 3.68%
 Yang et al 2015, 32.26, 1.96-531.83, 3.72%

Total (fixed effects): 33.40, 20.22-55.16, 100.00%

Q= 29.56;
 p=0.29;
 I²= 12.05%;
 95% CI for I²= 0.00-44.45

Figure 3

Forest plot of RASSF1A methylation and NPC risk using fix-effects model.

Figure 4

Funnel plot of RASSF1A methylation and NPC risk based on the fix-effects model

Figure 5

Forest plot of RASSF1A methylation and NPC risk using fix-effects model after removed the relative poor-quality studies

Figure 6

Funnel plot of RASSF1A methylation and NPC risk based on the fix-effects model after removed the relative poor-quality studies